報價延遲最少15分鐘:2024/12/24 12:58 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.8981 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.75/-1.50
|
|
企業價值
27.93M
|
| 資產負債 |
|
每股賬面淨值
3.57
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
-2,850,818
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:58 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology. |